Past, present and future of obesity pharmacotherapy

Czech version

Authors: Ľ. Fábryová
Authors‘ workplace: Metabol KLINIK s. r. o., Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, Bratislava, Slovenská republika, vedúci lekár MUDr. Ľubomíra Fábryová, PhD.
Published in: Vnitř Lék 2010; 56(10): 1058-1064
Category: Obesity 2010

Overview

Obese (BMI ≥ 30 kg/ m²) and overweight (BMI ≥ 25 and < 30 kg/ m²) individuals are at high risk of developing serious chronic health problems, including type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease. Caloric restriction, increased physical activity and behavioral therapy remain the primary treatment options for the management of body weight in these individuals. When a weight loss of 5 –⁠ 10% cannot be achieved in 3 –⁠ 6 months by lifestyle changes drug therapy might be indicated. This review will provide a brief history of obesity pharmacotherapy, discuss the status of currently available obesity drugs and outline the future drug development. A medical need exists for the development of novel weight loss therapies or combinations of known therapies.

Key words:
obesity –⁠ pharmacotherapy –⁠ orlistat –⁠ combination therapy –⁠ new antiobesitics

Sources

1. World Health Organization. Obesity and overweight. Fact Sheet No. 311. September 2006. Available from: http:/ / www.who.intlmediacentre/ factsheets/ fs311/ en/ index.html.

2. Aronne LJ, Nelinson DS, Lillo JL et al. Obesity as a disease state: a new paradigm for diagnosis and treatment. Clin Cornerstone 2009; 9 : 9 –⁠ 29.

3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89 : 2583 –⁠ 2589.

4. Tsigos K, Hainer V, Basdevant A et al. Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1 : 106 –⁠ 116.

5. Tsigos C, Hainer V, Basdevant A et al. Obesity Management Task Force Európskej obezitologickej spoločnosti (European Association for the Study of Obesity) Liečba obezity u dospelých: Európske odporúčania pre klinickú prax. Diabetes a obezita 2009; 17 : 10 –⁠ 20.

6. Fried M, Hainer V, Basdevant A et al. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obes Surg 2007; 17 : 260 –⁠ 270.

7. Fried M, Hainer V, Basdevant A et al. Interdisciplinárne európske odporúčania pre chirurgickú liečbu ťažkej obezity. Diabetes a obezita 2009; 17 : 22 –⁠ 28.

8. Weigle DS. Pharmacological therapy of obesity: past, present and future. J Clin Endocrinol Metab 2003; 88 : 2462 –⁠ 2469.

9. Council on Pharmacy and Chemistry 1935. Dinitrophenol not acceptable for N. N. R. JAMA 1935; 105 : 31 –⁠ 33.

10. Smith HJ, Roche AH, Jausch MF et al. Cardiomyopathy associated with amphetamine administration. Am Heart J 1976; 91 : 792 –⁠ 797.

11. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27 : 160 –⁠ 171.

12. Mark EJ, Patalas ED, Chang HT et al. Fatal pulmonary hypertension associated with short‑term use of fenfluramine and phentermine. N Engl J Med 1997; 337 : 602 –⁠ 606.

13. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine -⁠ phentermine. N Engl J Med 1997; 337 : 581 –⁠ 588.

14. Addy C, Jumes P, Rosko K et al. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid ‑⁠ 1 receptor (CB1R) inverse agonist. J Clin Pharmacol 2009; 49 : 1228 –⁠ 1238.

15. Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343 : 1826 –⁠ 1832.

16. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343 : 1833 –⁠ 1838.

17. Payer J, Hainer V, Ondrejka P et al. Sibutramin in obesity treatment (multicenter, open, prospective 12 -⁠ month ‑⁠ long study). Vnitř Lék 2004; 50 : 825 –⁠ 829.

18. James WP. The SCOUT study: risk‑benefit profile of sibutramine in overweight high risk cardiovascular patients. Eur Heart J Suppl 2005; 7 (Suppl L): L44 –⁠ L48.

19. Torp -⁠ Pedersen C, Caterson I, Coutinho Wet al. SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high‑risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28 : 2915 –⁠ 2923.

20. Weeke P, Andersson C, Fosbøl EL et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus –⁠ an analysis from the SCOUT lead ‑⁠ in period. BMC Endocr Disord 2010; 10 : 3.

21. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti‑obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl L): L32 –⁠ L38.

22. McClendon K, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf 2009; 8 : 724 –⁠ 744.

23. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 : 155 –⁠ 161.

24. Sjöström L. Analysis of the XENDOS study (Xenical in the prevention of diabetes in obese subjects). Endocr Pract 2006; 12 (Suppl 1): 31 –⁠ 33.

25. Rössner S, Sjöström L, Noack R et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8 : 49 –⁠ 61.

26. Bray GA. Medications for weight reduction. Endocrinol Metab Clin North Am 2008; 37 : 923 –⁠ 942.

27. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007; 369 : 71 –⁠ 77.

28. Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo ‑⁠ controlled trial. Obes Res 2000; 8 : 431 –⁠ 437.

29. Smith SR, Prosser WA, Donahue DJ et al. Lorcaserin (APD356), a selective 5 -⁠ HT(2C) agonist, reduces body weight in obese men and women. Obesity 2009; 17 : 494 –⁠ 503.

30. Akbas F, Gasteyger A, Sjödin A et al. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 2009; 10 : 58 –⁠ 67.

31. Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother 2009; 10 : 921 –⁠ 925.

32. Adis Data Information BV. Naltrexone/ Bupropion Contrave; Naltrexone SR/ Bupropion SR. Drugs RD 2010; 10 : 25 –⁠ 32.

33. Kopelman P, Bryson A, Hickling R et al. Cetilistat (ATL ‑⁠ 962), a novel lipase inhibitor: a 12‑week randomized, placebo ‑⁠ controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31 : 494 –⁠ 499.

34. Siddiqui NI. Incretin mimetics and DPP ‑⁠ 4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J 2009; 18 : 113 –⁠ 124.

35. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007; 99 : 68B –⁠ 79B.

36. Svačina Š. Léčba obezity u metabolického syndromu. Vnitř Lék 2009; 55 : 622 –⁠ 625.

37. Bhushan R, Elkind ‑⁠ Hirsch KE, Bhushan M et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr pract 2008; 14 : 993 –⁠ 999.

38. Moran TH, Dailey MJ. Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology 2009; 150 : 2526 –⁠ 2530.

39. Ravussin E, Smith SR, Mitchell JA. Enhanced weight loss with pramlintide/ metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009; 17 : 1736 –⁠ 1743.

40. Smith SR, Aronne LJ, Burns CM et al. Sustained weight loss following 12 -⁠ months pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31 : 1816 –⁠ 1823.